相关实验视频

Updated: Feb 21, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

儿科心脏伴侣3的短期结果左心室辅助装置:单个中心体验体验

Mohannad Dawary¹, Dimpna Albert-Brotons², Felix W Tsai¹

¹King Faisal Specialist Hospital & Research Center, Heart center, Cardiac surgery.

ESC heart failure

|February 19, 2026

概括

在沙特阿拉伯,HeartMate 3 (HM3) 室腔辅助器件 (VAD) 在患有末期心力衰竭的儿科患者中显示出有希望的短期结果. 这种VAD是先进的儿科心力衰竭管理的可行选择.

科学领域:

儿童心脏病学儿童心脏病学
机械循环支持机械循环支持
心脏外科手术心脏外科手术

背景情况:

儿科心力衰竭是一种严重的疾病,需要先进的治疗.
心脏移植受限于供体的可用性,需要像心室辅助装置 (VAD) 这样的替代方案.
HeartMate 3 (HM3) VAD已在成年人中确立,但儿科数据有限.

研究的目的:

评估沙特阿拉伯第一个儿科HeartMate 3 (HM3) VAD计划的短期结果.
评估HM3 VAD在末期心力衰竭儿童的安全性和有效性.

主要方法:

在2022-2024年期间接受HM3 VAD的15名儿科患者的回顾性队列研究.
对术后结果的分析,包括中风,血栓形成,感染,死亡率和移植率.
一年后生存率和无移植生存率的评估.

主要成果:

队列 (平均年龄11.07岁) 主要患有扩张性心肌病 (87%).
并发症包括中风 (13%),驱动线感染 (14%) 和装置血栓 (7%). 住院死亡率为13%.
一年生存率为87%,其中60%接受了成功的移植. 一年没有移植的生存率为55%.

结论:

心脏Mate 3 (HM3) LVAD在儿科末期心力衰竭中表现出良好的安全性和存活率.
在沙特儿科患者中,HM3 VAD是晚期心力衰竭的可行选择.
需要进一步的研究来确定HM3 VAD在儿童中的长期结果.

关键词:

最终阶段的心力衰竭.心脏移植心脏移植手术腹腔室辅助器件可以帮助心室.

更多相关视频

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

相关概念视频

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...